Blue7

Blue7

Blue7 was established in Singapore by Juanita FU and MA Hui Hsing. Both hold advanced degrees in life sciences and business; FU earned an MD from the University of Southern California and MA completed an MS in Biotechnology from Johns Hopkins. The office deploys capital across venture, private equity funds, and ESG equity strategies without a disclosed single-family wealth source. Blue7 targets Seed and Series A rounds in Asia. Confirmed positions include direct exposure to Foundation Healthcare Holdings alongside Seatown Holdings, East Ventures, EMTEK, Orbit Malaysia, and Citrine Capital. The firm also holds positions in Bittensor and Render Network. Allocations occur via direct co-investments, SPVs, fund-of-funds vehicles, and private credit. Geographic focus remains Asia with emphasis on ventures that combine technology and sustainability metrics. The team includes Denzyl KHOO on the investment side and Genevieve HENG as Senior Advisor. Blue7 maintains professional ties to the CAIA Association, CFA Institute, IIX Partner Network, and Global Private Capital Association. In February 2024 Suguna Sureshkumar delivered a keynote on Blockchain and AI at the Royal Investment Summit on behalf of the firm. Blue7 operates with a hybrid mandate that blends multi-family office capital with impact requirements. Co-founders retain GP roles in separate life-science vehicles while the office itself functions as an allocator rather than an operating company. This structure separates investment decisions from any single family branch.